Depo-Provera Rule 702 Hearing: What’s at Stake at the July 27, 2026 Ruling

Last updated: July 7, 2026

Table of Contents

1. What Is the Depo-Provera Rule 702 Hearing, and Why Did It Move to July 27?
2. Why the Hearing Still Matters After the Settlement Announcement
3. The Science Behind the Lawsuits
4. Toney v. Pfizer: The Bellwether Case That Was Vacated
5. What Happens After July 27
6. Do You Need to Act Before the Ruling?
7. FAQ

What Is the Depo-Provera Rule 702 Hearing, and Why Did It Move to July 27?

The Depo-Provera Rule 702 hearing is a “gatekeeping” proceeding where a judge decides whether expert witnesses can testify to a jury at all, before any trial begins. In the Depo-Provera MDL, Judge Rodgers originally scheduled this hearing for June 24-25, 2026, to evaluate whether plaintiffs’ general-causation experts could testify that Depo-Provera is capable of causing intracranial meningioma.

According to the court’s June 15 order, the hearing was pushed back to July 27, 2026, in Pensacola, Florida, to give the parties time to finalize the terms of a global settlement announced that same day. The court still expects to rule on the underlying Rule 702 motions “in the ordinary course,” since the settlement will not cover every pending case.

Why the Hearing Still Matters After the Settlement Announcement

A pending settlement does not end the litigation. Judge Rodgers specifically noted that the parties’ global agreement, once finalized, “will not resolve all cases in the MDL,” because only plaintiffs who meet eligibility criteria still being negotiated will have the option to participate. For everyone else — including many of the more than 5,800 plaintiffs currently pending in the federal MDL as of July 2026, plus women pursuing claims in state courts in New York and Delaware, where the settlement is not expected to apply — the July 27 causation ruling determines whether their claims can move toward trial at all.

Plaintiffs who did not separately request permission to submit their own general-causation experts or additional briefing will be bound by whatever ruling comes out of the July 27 hearing, per the court’s June 15 order.

The Science Behind the Lawsuits

The litigation traces back to a national case-control study published in The BMJ in March 2024, which examined progestogen use among more than 108,000 French women. Researchers found that women who used injectable medroxyprogesterone acetate — the active ingredient in Depo-Provera — had 5.55 times the odds of developing an intracranial meningioma compared with non-users, an association driven largely by prolonged use of a year or more.

This is the general-causation science the July 27 hearing addresses: not whether any individual woman’s meningioma was caused by Depo-Provera, but whether the underlying science is sound enough for expert witnesses to say so at trial at all.

Toney v. Pfizer: The Bellwether Case That Was Vacated

Toney v. Pfizer Inc. was one of the early cases moving toward the first scheduled bellwether trial in the MDL, previously set for December 7, 2026. Following the June 15 settlement announcement, Judge Rodgers vacated all trial and pretrial deadlines in that case, effectively removing the immediate need for it to proceed as the litigation’s first test trial.

That does not mean bellwether trials are off the table permanently. A separate order issued the same day, Pretrial Order No. 30A, makes clear the global agreement will not resolve every case, so additional test trials remain possible for claims that fall outside the settlement’s eligibility criteria once those are finalized.

What Happens After July 27

Two tracks are now running in parallel in MDL No. 3140. On one track, Pfizer and plaintiffs’ leadership are working to finalize settlement terms, including eligibility requirements and payout amounts, none of which had been publicly disclosed as of this writing. On the other track, the court continues to move the litigation forward for cases the settlement won’t reach, starting with the July 27 causation ruling.

Monthly case management conferences are scheduled through the rest of 2026, where the court will address how the settlement structure applies across the MDL and how any remaining, non-settling cases proceed toward trial.

You can review TortAdvisor’s broader active lawsuits and mass tort litigation tracker for updates across other pending cases while these two tracks play out.

Do You Need to Act Before the Ruling?

Attorneys are generally still accepting new Depo-Provera cases while the settlement and the Rule 702 ruling both remain unresolved. Because eligibility criteria for the settlement have not been finalized, and because state-court cases in places like New York and Delaware are not expected to be covered by the federal settlement at all, waiting for more clarity can mean losing time against a filing deadline. If you received two or more Depo-Provera (or Depo-SubQ Provera 104) injections and were later diagnosed with an intracranial or spinal meningioma, you can estimate what your case could be worth now or see if you may qualify for a similar recovery based on how earlier claims in this litigation have been evaluated.

Frequently Asked Questions

1. What is the Rule 702 hearing in the Depo-Provera lawsuit?
It is a hearing where Judge M. Casey Rodgers will decide whether plaintiffs’ expert witnesses can testify that Depo-Provera is capable of causing intracranial meningioma. The ruling applies broadly across MDL No. 3140 and determines whether that scientific testimony can be presented at trial in cases the settlement doesn’t resolve.

2. Why was the Depo-Provera Daubert hearing moved to July 27, 2026?
The hearing, originally set for June 24-25, 2026, was rescheduled after Pfizer and plaintiffs’ leadership announced a global settlement agreement in principle on June 15, 2026, giving the parties time to finalize settlement terms.

3. Does the Depo-Provera settlement mean the lawsuits are over?
No. The court’s June 15 order made clear the settlement will not resolve every case in the MDL. Plaintiffs who don’t meet the eventual eligibility criteria, along with most state-court plaintiffs in New York and Delaware, will still depend on rulings like the July 27 Rule 702 decision.

4. What happened to the Depo-Provera bellwether trial?
The first scheduled bellwether trial, Toney v. Pfizer Inc., had its trial and pretrial deadlines vacated by Judge Rodgers on June 15, 2026, following the settlement announcement, removing the immediate need for that trial to proceed as scheduled for December 7, 2026.

5. Can I still file a Depo-Provera lawsuit while the settlement and Rule 702 ruling are pending?
Yes. Attorneys are generally still accepting new cases for women diagnosed with a meningioma after Depo-Provera use. Because eligibility terms for the settlement are not yet final, a case review can help clarify options based on individual diagnosis and use history.

Related Posts

• Depo-Provera Settlement 2026: What the New Global Agreement Means for Your Claim
• Depo-Provera Daubert Hearing 2026: June 24 Date, 6,000 Cases and What It Means
• Depo Provera Brain Tumor Lawsuit 2026: Who Qualifies

External sources: U.S. District Court, Northern District of Florida — MDL No. 3140 docket page; Roland N, et al., The BMJ (2024), via PubMed/NIH.